암 유전자 치료 시장 : 유형별, 치료법별, 제품별, 최종 용도별 - 세계 예측(2024-2032년)

Cancer Gene Therapy Market size is projected to expand at 20.5% CAGR between 2024 and 2032, owing to the increasing prevalence of cancer worldwide. Strong advances in genetic engineering and biotechnology are facilitating the development of effective gene therapies. The growing investments from pharmaceutical companies and government initiatives are further supporting research and clinical trials.

According to data from the American Cancer Society, the U.S. is estimated to have 2,001,140 new cancer cases in 2024. The rising preference of patients for personalized medicine is driving the demand for gene therapy for cancer treatment. The growing awareness about the potential of gene therapy to target cancer at the molecular level is adding to its high appeal. Innovative developments in delivery systems and the ongoing clinical successes are bolstering the credibility and interest in gene therapy, adding to the market growth.

The overall industry is segregated into type, therapy, product, end-use, and region.

Based on type, the ex-vivo segment is projected to account for sizeable share of the cancer gene therapy market by 2032, owing to its high precision and effectiveness. Ex-vivo therapy allows the modification of patient cells outside the body for ensuring targeted and controlled genetic alterations. The advances in cell culture technologies and improved delivery mechanisms are improving efficacy. The increasing success rates in clinical trials and the growing demand for personalized cancer treatments are accelerating the segment growth.

In terms of end-use, the cancer gene therapy industry size from the research institutes segment is estimated to grow at significant rate from 2024 to 2032, due to the increasing funding and investments in cancer research. Leading research institutes are focusing on the development of innovative gene therapy techniques, advancing scientific understanding, and conducting clinical trials. The collaboration with pharmaceutical companies and government support are also accelerating the adoption of these therapies in research institutes.

Regionally, the Asia Pacific cancer gene therapy industry is projected to depict substantial gains between 2024 and 2032, on account of the rising cancer prevalence and increasing awareness of advanced treatments in the region. The launch of government initiatives and funding are supporting R&D in gene therapy. The advances in biotechnology and genetic engineering are enhancing treatment efficacy. The collaborations between local research institutes and global pharmaceutical companies for innovations will favor the regional market growth.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising R&D investments and demand for novel cancer therapeutics
    • 3.2.1.2 Technological advancements in gene therapy
    • 3.2.1.3 Increasing incidence of cancer
    • 3.2.1.4 Increasing number of product approvals and launches
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of therapy
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Porter's analysis
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive positioning matrix
• 4.4 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Million)

• 5.1 Key trends
• 5.2 Ex-vivo
• 5.3 In-vivo

Chapter 6 Market Estimates and Forecast, By Therapy, 2021 - 2032 ($ Million)

• 6.1 Key trends
• 6.2 Oncolytic virotherapy
• 6.3 Gene-induced immunotherapy
• 6.4 Gene transfer

Chapter 7 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Million)

• 7.1 Key trends
• 7.2 Viral vectors
  • 7.2.1 Adenoviruses
  • 7.2.2 Lentiviruses
  • 7.2.3 Retrovirus
  • 7.2.4 Adeno associated virus
  • 7.2.5 Herpes simplex virus
  • 7.2.6 Vaccinia virus
  • 7.2.7 Other viral vectors
• 7.3 Non-viral vectors
• 7.4 Other products

Chapter 8 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Million)

• 8.1 Key trends
• 8.2 Biopharma companies
• 8.3 Research institutes
• 8.4 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Million)

• 9.1 Key trends, by region
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 Rest of Asia Pacific
• 9.5 Rest of the World

Chapter 10 Company Profiles

• 10.1 Abeona Therapeutics Inc.
• 10.2 Altor Bioscience Inc.
• 10.3 Asklepios BioPharmaceutical Inc.
• 10.4 Bluebird bio, Inc.
• 10.5 Bristol-Myers Squibb Company
• 10.6 Elevate Bio
• 10.7 Genelux Corporation
• 10.8 GlaxoSmithKline Inc.
• 10.9 Introgen Therapeutics Inc.
• 10.10 Merck KGaA
• 10.11 Novartis AG